|
1) Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997; 126: 441-9
|
|
|
|
2) Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet. 1998; 352: 1649-55
|
|
|
|
|
3) Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002; 346: 1437-44
|
|
|
|
|
|
4) Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res. 2009; 83: 436-43
|
|
|
|
|
|
5) Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002; 110: 625-32
|
|
|
|
|
|
6) Freestone T, Turner RJ, Coady A, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995; 15: 1145-51
|
|
|
|
|
|
7) Bode MK, Soini Y, Melkko J, et al. Increased amount of type III pN-collagen in human abdominal aortic aneurysms: evidence for impaired type III collagen fibrillogenesis. J Vasc Surg. 2000; 32: 1201-7
|
|
|
|
|
|
8) Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res. 2008; 102: 1368-77
|
|
|
|
|
|
9) Cornuz J, Sidoti Pinto C, Tevaearai H, et al. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health. 2004; 14: 343-9
|
|
|
|
|
|
10) Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009; 15: 467-78
|
|
|
|
|
|
11) Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg. 2006; 43: 117-24
|
|
|
|
|
|
12) Shiraya S, Miyake T, Aoki M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis. 2009; 202: 34-40
|
|
|
|
|
|
13) Sukhija R, Aronow WS, Sandhu R, et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006; 97: 279-80
|
|
|
|
|
|
14) Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006; 32: 21-6
|
|
|
|
|
|
15) Daugherty A, Manning MW Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000; 105: 1605-12
|
|
|
|
|
|
16) Kato H, Iwai N, Inui H, et al. Regulation of vascular angiotensin release. Hypertension. 1993; 21: 446-54
|
|
|
|
|
|
17) Liao S, Miralles M, Kelley BJ, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg. 2001; 33: 1057-64
|
|
|
|
|
|
18) Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet. 2006; 368: 659-65
|
|
|
|
|
|
19) Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312: 117-21
|
|
|
|
|
|
20) Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol. 2001; 134: 865-70
|
|
|
|
|
|
21) Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007; 369: 1431-9
|
|
|
|
|
|
22) Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg. 2001; 88: 1066-72
|
|
|
|
|
|
23) Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001; 34: 606-10
|
|
|
|
|
|
24) Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999; 100: 48-54
|
|
|
|
|
|
25) Leach SD, Toole AL, Stern H, et al. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg. 1988; 123: 606-9
|
|
|
|
|
|
26) Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007; 117: 3359-68
|
|
|
|
|
|
27) Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005; 11: 1330-8
|
|
|
|
|
|
28) Miyake T, Aoki M, Masaki H, et al. Regression of abdominal aortic aneurysms by simultaneous inhibition of nuclear factor kappaB and ets in a rabbit model. Circ Res. 2007; 101: 1175-84
|
|
|
|
|